Global X Robotics and Artificial Intelligence ETF vs Smith & Nephew plc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $36.21, while Smith & Nephew plc trades at $30.06 (market cap $12.40B). The key difference: Smith & Nephew plc pays a 2.62% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| BOTZ | SNN | |
|---|---|---|
52-Week High | $41.63 | $38.70 |
52-Week Low | $31.99 | $28.73 |
Market Cap | — | $12.40B |
Sector | — | Health |
Enterprise Value | — | $15.17B |
Dividend Yield | — | 2.62% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $31.08, up 1.24% with a bullish technical signal. The company shows improving fundamentals with 2024 revenue of $5.81B and net income of $412M, while recent earnings beat expectations. Strong cash flow generation and new product launches in robotics and wound care support growth. Analyst consensus is mixed with 27% buy ratings but majority holds.
Outlook remains positive with projected revenue growth and margin expansion, though recent earnings misses and elevated valuation metrics pose risks. The stock's technical strength and fundamental recovery present opportunity, but investor caution is warranted given mixed analyst sentiment and competitive pressures in medical technology.
Trailing returns across standard periods
Latest headlines on both assets
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →